184 related articles for article (PubMed ID: 32064596)
21. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
[TBL] [Abstract][Full Text] [Related]
22. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
23. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
[No Abstract] [Full Text] [Related]
24. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
[TBL] [Abstract][Full Text] [Related]
25. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
[No Abstract] [Full Text] [Related]
26. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
27. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
28. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
[TBL] [Abstract][Full Text] [Related]
29. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
30. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
31. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
Krakowski AC; Nguyen TA
Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
[TBL] [Abstract][Full Text] [Related]
32. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
33. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
34. Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex.
Ghazavi M; Taheri S; Sabzghabaee AM; Tavakolifard N; Yaghini O; Faghihi G; Afshar K; Abtahi-Naeini B
J Res Pharm Pract; 2022; 11(4):144-150. PubMed ID: 37969618
[TBL] [Abstract][Full Text] [Related]
35. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
Dao DD; Pixley JN; Akkurt ZM; Feldman SR
Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.
Lin YT; Yu CL; Tu YK; Chi CC
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453576
[TBL] [Abstract][Full Text] [Related]
37. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
[TBL] [Abstract][Full Text] [Related]
38. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
39. Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.
Ebrahimi-Fakhari D; Müller CSL; Meyer S; Flotats-Bastardas M; Vogt T; Pföhler C
Dermatol Ther (Heidelb); 2017 Mar; 7(1):175-179. PubMed ID: 28181194
[TBL] [Abstract][Full Text] [Related]
40. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]